MedPath

Phenex Pharmaceuticals Aktiengesellschaft

Phenex Pharmaceuticals Aktiengesellschaft logo
🇩🇪Germany
Ownership
Holding
Established
2002-01-01
Employees
11
Market Cap
-
Website
http://www.phenex-pharma.com

Clinical Trials

4

Active:1
Completed:3

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients

Phase 2
Completed
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
First Posted Date
2013-12-03
Last Posted Date
2016-09-29
Lead Sponsor
Phenex Pharmaceuticals AG
Target Recruit Count
12
Registration Number
NCT01999101
Locations
🇦🇹

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Vienna, Austria

Multiple Ascending Oral Dose Phase I Study With Px-102

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2013-12-02
Last Posted Date
2014-11-04
Lead Sponsor
Phenex Pharmaceuticals AG
Target Recruit Count
42
Registration Number
NCT01998672
Locations
🇩🇪

FOCUS Clinical Drug Development GmbH, Neuss, Germany

Single Ascending Oral Dose Phase I Study With Px-102

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2013-12-02
Last Posted Date
2014-11-04
Lead Sponsor
Phenex Pharmaceuticals AG
Target Recruit Count
54
Registration Number
NCT01998659
Locations
🇩🇪

FOCUS Clinical Drug Development GmbH, Neuss, Germany

News

No news found
© Copyright 2025. All Rights Reserved by MedPath